Clinical Trials Logo

Filter by:
NCT ID: NCT04755790 Completed - Clinical trials for Amputation; Traumatic, Hand

To Assess the Utility of the Point Digit in a Clinical Take-home Study

Start date: May 18, 2020
Phase: N/A
Study type: Interventional

This study will allow us to assess whether the Point Digit confers functional and psychological benefit to persons with partial hand amputations in an unconstrained environment. The use of the Point Digit outside of the laboratory will allow for a wider variety of uses and for a more realistic simulation of the product being used in the field. This well-controlled trial (without randomization of subjects) will produce the first Level II-1 medical evidence in our field of partial hand prosthetic design as described by the 1989 U.S. Preventive Services Task Force. Furthermore, this study will provide important data to support providers who are requesting reimbursement from payers.

NCT ID: NCT04755777 Completed - Sepsis Clinical Trials

Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

Start date: October 22, 2020
Phase:
Study type: Observational

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

NCT ID: NCT04755673 Completed - Clinical trials for Irritable Bowel Syndrome

Atrantil for Intestinal Bacterial Overgrowth

Start date: September 18, 2020
Phase: N/A
Study type: Interventional

Intestinal Bacterial Overgrowth (IBO) is a common functional condition due to excessive amounts of bacteria in the gastrointestinal tract. These bacteria ferment ingested food resulting in the production of hydrogen, methane, and carbon dioxide which subsequently can induce GI symptoms including abdominal pain, bloating, distention, diarrhea and constipation. Typically this condition is treated with antibiotics but for a portion of patients symptoms often recur. Recent work suggests that increased methane production may emanate from overgrowth of a specific type of archaebacteria, causing the aforementioned symptoms. However, no current therapies exist to treat this phenomenon. The investigators propose to trial the supplement Atrantil on patients with IMO in order to study the supplements impact on symptoms, quality of life, and methane levels.

NCT ID: NCT04755595 Completed - Clinical trials for Dermatological Non-Disease

Combination Facial Aesthetic Treatment in Millennials

Start date: March 9, 2021
Phase: Phase 2
Study type: Interventional

With 63% of consumers willing to consider investing in facial aesthetics and 73% of consumers worldwide expecting to invest in aesthetic treatments in the upcoming year, it is imperative to explore patient satisfaction and psychosocial impact of a multimodal aesthetic treatment in a millennial cohort. The investigators hypothesize that a combination approach to facial aesthetic treatment in a millennial cohort will result in increased patient-reported satisfaction in multiple areas, including perception of aging concerns and quality of life.

NCT ID: NCT04755426 Completed - Clinical trials for Aortic Stenosis Symptomatic

Understanding Patient Goals and Preferences to Facilitate Shared Decision Making for Symptomatic Aortic Stenosis

Start date: January 9, 2020
Phase:
Study type: Observational

The overall goal of this study is to develop and validate a preference assessment tool for patients who have severe aortic stenosis and are contemplating their treatment options. The first part of the study focuses on understanding the treatment goals and treatment features that matter most to patients who have already made the decision. The investigators use mixed methods (nominal group technique, card sorting) to elicit, prioritize, and organize these patient preferences into a "cognitive map". Based on those findings, the investigators design a preference tool and then pre-test the tool with patients and healthcare providers.

NCT ID: NCT04755348 Completed - Tobacco Use Clinical Trials

A Study to Assess the Pharmacokinetics of Oral Nicotine Pouches and Lozenges in Healthy Adults

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

This is a randomised, open-label, confined, cross-over study to evaluate the nicotine pharmacokinetics (PK) of modern oral nicotine pouches and nicotine lozenges carried out in 36 healthy adult subjects who smoke cigarettes and who may have experience using smokeless tobacco (loose or pouches).

NCT ID: NCT04755218 Completed - Pregnancy Clinical Trials

Labor Induction With Oral Versus Vaginal Misoprostol

Start date: May 24, 2021
Phase:
Study type: Observational

This study will compare vaginal and oral misoprostol, to determine whether a vaginal misoprostol regimen achieves a higher vaginal delivery rate in a real-world, high-volume setting, and whether this regimen reduces time and oxytocin need on a high-volume Labor and Delivery unit at Parkland Hospital. Our primary hypothesis is that among women with singleton, term pregnancies, cervical dilation 2cm or less, and indicated labor induction, the rate of vaginal delivery is significantly increased when a standardized vaginal misoprostol regimen is used, compared with a standardized oral misoprostol regimen.

NCT ID: NCT04755140 Completed - Heart Diseases Clinical Trials

Endoprosthesis Metal Toxicity Study

Start date: March 19, 2021
Phase:
Study type: Observational

The purpose of this research is to investigate whether patients who previously had endoprosthesis surgery experience memory, thinking, or heart problems. It will also help determine how often these problems occur.

NCT ID: NCT04755088 Completed - Renal Impairment Clinical Trials

Surufatinib Renal Impairment Study

Start date: February 12, 2021
Phase: Phase 1
Study type: Interventional

An open-label, multicenter, single-dose, single-period, sequential study to assess the effect of moderate renal impairment on the pharmacokinetics of surufatinib.

NCT ID: NCT04755075 Completed - Hepatic Impairment Clinical Trials

Surufatinib Hepatic Impairment Study

Start date: February 12, 2021
Phase: Phase 1
Study type: Interventional

An open-label, multicenter, single-dose, single-period, sequential study to determine the effect of hepatic impairment on the PK of surufatinib.